U.S. Mortgage Finance Stock News

NasdaqCM:ANNA
NasdaqCM:ANNARenewable Energy

AleAnna (ANNA) Q3 Profit Of US$3.3 Million Tests Loss Making Narrative

AleAnna (NasdaqCM:ANNA) has just posted another quarter of rapid top line expansion, with Q3 FY 2025 revenue of about US$11.2 million and basic EPS of US$0.08, against a backdrop of very large revenue growth of 2,471.5% over the past year while remaining unprofitable on a trailing 12 month view. Over recent periods the company has seen revenue move from roughly US$0.6 million in Q3 FY 2024 to US$11.2 million in Q3 FY 2025, while trailing 12 month EPS across the last reported quarters stayed...
NYSE:EFOR
NYSE:EFORIT

Quinnox Deal and Everforth Rebrand Could Be A Game Changer For ASGN (ASGN)

In its latest quarter, ASGN reported revenue and adjusted EBITDA margins ahead of expectations but missed EPS forecasts, while also outlining integration of the Quinnox acquisition and a rebranding to Everforth to consolidate its seven brands. This combination of earnings mixed with margin outperformance and a pivot toward higher-value consulting and unified branding could meaningfully reshape ASGN’s business mix and competitive positioning over time. We’ll now examine how ASGN’s Quinnox...
NYSEAM:KULR
NYSEAM:KULRElectrical

KULR Technology Group (KULR) Q4 Loss Of US$44.3 Million Tests Bullish Growth Narratives

KULR Technology Group (KULR) closed FY 2025 with fourth quarter revenue of US$2.9 million and a basic EPS loss of US$0.97, alongside a trailing twelve month EPS loss of US$1.56 on revenue of US$16.2 million. Over the last few quarters, the company has reported revenue between US$2.4 million and US$6.9 million per quarter, while quarterly EPS has ranged from a loss of US$0.54 to a gain of US$0.22. This leaves investors focusing on how quickly these top line changes might translate into...
NasdaqCM:FTLF
NasdaqCM:FTLFPersonal Products

FitLife Brands (FTLF) Margin Compression In FY 2025 Tests Bullish Growth Narratives

FitLife Brands (FTLF) has just closed out FY 2025 with fourth quarter revenue of US$25.9 million and basic EPS of US$0.17, alongside trailing twelve month revenue of US$81.5 million and EPS of US$0.68 that investors will be watching against the prior year’s figures. Over recent quarters the company has seen revenue move from US$15.0 million in Q4 FY 2024 to US$25.9 million in Q4 FY 2025, while quarterly EPS shifted from US$0.23 to US$0.17, setting the backdrop for the latest full year read on...
NasdaqGS:CHKP
NasdaqGS:CHKPSoftware

Check Point Software Technologies (CHKP) Margin Expansion To 38.8% Tests Bearish EPS Decline Narrative

Check Point Software Technologies (CHKP) closed out FY 2025 with fourth quarter revenue of US$744.9 million and basic EPS of US$2.85, while full year trailing EPS reached US$9.85 on revenue of US$2.7 billion and earnings grew 25% over the past 12 months. Over the last few reported periods, revenue has moved from US$703.7 million in Q4 2024 to US$744.9 million in Q4 2025, with quarterly basic EPS ranging from US$1.77 in Q1 2025 to US$3.34 in Q3 2025 and trailing net income rising from US$845.7...
NasdaqGS:DWSN
NasdaqGS:DWSNEnergy Services

Dawson Geophysical (DWSN) Returns To Quarterly Profit Challenging Volatility‑Focused Narratives

Dawson Geophysical (DWSN) closed out FY 2025 with fourth quarter revenue of US$26.9 million and basic EPS of US$0.02, alongside net income of US$0.6 million. This set a cleaner finish to a year where the trailing twelve month figures still show a loss of US$1.9 million on US$75.6 million of revenue and a basic EPS loss of US$0.06. Over recent quarters the company has seen quarterly revenue range from US$9.9 million to US$26.9 million, with EPS moving between a loss of US$0.08 and a profit of...
NasdaqGS:ALKS
NasdaqGS:ALKSBiotechs

Alkermes Narcolepsy Trials Spark Interest In Growth And Valuation Upside

Alkermes (NasdaqGS:ALKS) has begun Phase 3 clinical trials for alixorexton, its orexin 2 receptor agonist for narcolepsy type 1 and type 2. The late stage Brilliance Studies aim to evaluate alixorexton in patients with significant unmet treatment needs in sleep disorders. This marks a new development in Alkermes' pipeline beyond prior focus areas highlighted in earlier coverage. For Alkermes, known for its work in neuroscience and psychiatry, the Brilliance Studies add a new dimension to...
NasdaqGM:JFIN
NasdaqGM:JFINConsumer Finance

Does Jiayin Group’s (JFIN) Bigger Dividend And Buyback Hint At A Strategic Capital Shift?

Jiayin Group Inc. has reported its fourth-quarter and full-year 2025 results, showing quarterly revenue of CNY 1,090.2 million and net income of CNY 100.63 million, alongside full-year revenue of CNY 6,222.19 million and net income of CNY 1,535.74 million. Alongside these results, the company increased its dividend payout framework to target around 30% of prior-year net income and completed a share repurchase of 4,600,000 shares, equal to 8.6% of its share count, signaling a stronger focus...
NYSE:CNM
NYSE:CNMTrade Distributors

Core And Main Governance Shift Puts New Utility Expertise To Work

Core & Main (NYSE:CNM) has appointed former American Water Works CEO M. Susan Hardwick to its board, effective April 1. The company has restructured key governance roles, including a new board chair and a new audit committee chair. The longstanding executive chair has retired as part of the succession changes. Core & Main, trading at $49.4, is adjusting its leadership structure after a 3-year return of 121.8% and a 1-year return of 0.0%. The share price has seen a 2.3% decline over the past...
NasdaqCM:OCGN
NasdaqCM:OCGNBiotechs

Ocugen Hits Key Milestone In GARDian3 Stargardt Gene Therapy Program

Ocugen (NasdaqCM:OCGN) completed enrollment and dosing early in its pivotal Phase 2/3 GARDian3 trial for OCU410ST. The trial evaluates a one time gene therapy candidate for Stargardt disease, a severe inherited retinal disorder with no approved treatments. This is Ocugen's second late stage clinical program and aligns with its stated goal to submit multiple BLAs by 2028. For readers tracking gene therapy names, Ocugen sits at the intersection of rare ophthalmology and inherited retinal...
NasdaqGM:VERA
NasdaqGM:VERABiotechs

Vera Therapeutics Adds Experienced Legal Chief As Shares Trade Below Targets

Vera Therapeutics has appointed Jane Wright-Mitchell as its new Chief Legal Officer. Wright-Mitchell brings extensive legal, compliance, and intellectual property experience in life sciences and pharmaceuticals. The appointment adds senior leadership depth as Vera Therapeutics continues to develop its pipeline. The new Chief Legal Officer steps in at a time when Vera Therapeutics, listed as NasdaqGM:VERA, is trading at $40.23. The share price reflects a mixed return profile, with a 1.2%...
NYSE:SUI
NYSE:SUIResidential REITs

Is Sun Communities (SUI) Offering A Compelling Valuation After Recent Share Price Pullback?

If you are wondering whether Sun Communities at around US$125.96 is offering fair value right now, you are not alone, many investors are asking the same question. The stock’s recent returns have been mixed, with a 2.2% decline over the last week, a 7.7% decline over the last month, but a 3.1% gain year to date and 4.8% over the past year. These moves come as Sun Communities continues to attract attention as a Residential REIT, with investors weighing its track record over the last 3 and 5...
NasdaqGS:FSUN
NasdaqGS:FSUNBanks

FirstSun Index Exit Raises Questions On Liquidity And Undervalued Shares

FirstSun Capital Bancorp (NasdaqGS:FSUN) has been removed from the Russell 2000 Defensive Index. The company has also been dropped from the Russell 2500 Defensive, Russell 2500 Value-Defensive, and Russell 2000 Value-Defensive indices. This index reclassification affects how some passive and rules based funds may hold or view the stock. FirstSun Capital Bancorp, the holding company for FirstBank, operates as a regional banking platform focused on commercial and consumer financial services...
NasdaqGS:SHOP
NasdaqGS:SHOPIT

Exploring 3 High Growth Tech Stocks In The US Market

In the last week, the United States market has stayed flat but is up 16% over the past year, with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for sustained revenue and earnings expansion in alignment with these broader market trends.
NYSE:KVYO
NYSE:KVYOSoftware

3 Insider-Owned Growth Companies With Up To 81% Earnings Expansion

In the last week, the United States market has stayed flat, yet it has risen by 16% over the past year with expectations of a 15% annual earnings growth in the coming years. In this context, identifying growth companies with high insider ownership can be advantageous as they often align management interests with shareholder value and may capitalize on favorable market conditions.
NYSE:SNAP
NYSE:SNAPInteractive Media and Services

3 Penny Stocks With Market Caps Under $19B To Watch

The market remained flat over the last week, but it is up 16% over the past year, with earnings expected to grow by 15% annually in the coming years. For those interested in smaller or newer companies, penny stocks—despite their somewhat outdated name—can still offer surprising value and potential for growth. By focusing on stocks with strong financial foundations, investors may find opportunities that combine stability with promising prospects.